Overall CNS gets a fundamental rating of 5 out of 10. We evaluated CNS against 238 industry peers in the Capital Markets industry. While CNS has a great profitability rating, there are some minor concerns on its financial health. CNS is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

CNS had positive earnings in the past year.
CNS had a negative operating cash flow in the past year.
Each year in the past 5 years CNS has been profitable.
CNS had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

CNS has a Return On Assets of 20.48%. This is amongst the best in the industry. CNS outperforms 97.48% of its industry peers.
CNS has a better Return On Equity (29.83%) than 95.38% of its industry peers.
Looking at the Return On Invested Capital, with a value of 24.42%, CNS belongs to the top of the industry, outperforming 97.90% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	20.48%
ROE	29.83%
ROIC	24.42%

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CNS has a Profit Margin of 29.73%. This is in the better half of the industry: CNS outperforms 73.53% of its industry peers.
CNS's Profit Margin has improved in the last couple of years.
CNS has a better Operating Margin (33.83%) than 65.13% of its industry peers.
CNS's Operating Margin has declined in the last couple of years.
CNS has a Gross Margin of 88.60%. This is amongst the best in the industry. CNS outperforms 92.86% of its industry peers.
CNS's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	33.83%
PM (TTM)	29.73%
GM	88.6%

OM growth 3Y-4.66%

OM growth 5Y-2.01%

PM growth 3Y-3.48%

PM growth 5Y8.65%

GM growth 3Y0.67%

GM growth 5Y0.08%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CNS has an Altman-Z score of 9.03. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
CNS's Altman-Z score of 9.03 is amongst the best of the industry. CNS outperforms 93.70% of its industry peers.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	9.03

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.79 indicates that CNS may have some problems paying its short term obligations.
CNS has a worse Current ratio (0.79) than 63.03% of its industry peers.
CNS has a Quick Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CNS (0.79) is worse than 62.60% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.79
Quick Ratio	0.79

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CNS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.80%.
Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 3.74% on average per year.
CNS shows a small growth in Revenue. In the last year, the Revenue has grown by 7.04%.
Measured over the past years, CNS shows a small growth in Revenue. The Revenue has been growing by 5.73% on average per year.

EPS 1Y (TTM)5.8%

EPS 3Y-5.81%

EPS 5Y3.74%

EPS Q2Q%3.85%

Revenue 1Y (TTM)7.04%

Revenue growth 3Y-0.12%

Revenue growth 5Y5.73%

Sales Q2Q%-5.55%

3.2 Future

Based on estimates for the next years, CNS will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.66% on average per year.
Based on estimates for the next years, CNS will show a small growth in Revenue. The Revenue will grow by 6.70% on average per year.

EPS Next Y8.49%

EPS Next 2Y8.3%

EPS Next 3Y8.22%

EPS Next 5Y8.66%

Revenue Next Year8.33%

Revenue Next 2Y7.78%

Revenue Next 3Y7.24%

Revenue Next 5Y6.7%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 20.73, the valuation of CNS can be described as rather expensive.
CNS's Price/Earnings ratio is a bit more expensive when compared to the industry. CNS is more expensive than 60.08% of the companies in the same industry.
When comparing the Price/Earnings ratio of CNS to the average of the S&P500 Index (28.32), we can say CNS is valued slightly cheaper.
CNS is valuated rather expensively with a Price/Forward Earnings ratio of 19.11.
CNS's Price/Forward Earnings ratio is in line with the industry average.
CNS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.57.

		Industry Rank	Sector Rank
PE	20.73
Fwd PE	19.11

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than the industry average as 78.99% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	16.04

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of CNS may justify a higher PE ratio.

PEG (NY)2.44

PEG (5Y)5.54

EPS Next 2Y8.3%

EPS Next 3Y8.22%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CNS has a Yearly Dividend Yield of 3.84%. Purely for dividend investing, there may be better candidates out there.
CNS's Dividend Yield is comparable with the industry average which is at 6.02.
CNS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.83.

		Industry Rank	Sector Rank
Dividend Yield	3.84%

5.2 History

The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend in the last 3 years.

Dividend Growth(5Y)-7.12%

Div Incr Years2

Div Non Decr Years2

5.3 Sustainability

CNS pays out 76.25% of its income as dividend. This is not a sustainable payout ratio.

DP76.25%

EPS Next 2Y8.3%

EPS Next 3Y8.22%

More info and screens

Find the best dividend stocks

Show peers with best dividend

COHEN & STEERS INC / CNS FAQ

What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CNS.

What is the valuation status for CNS stock?

ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.

Can you provide the profitability details for COHEN & STEERS INC?

COHEN & STEERS INC (CNS) has a profitability rating of 7 / 10.

Can you provide the financial health for CNS stock?

The financial health rating of COHEN & STEERS INC (CNS) is 5 / 10.

What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?

The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 8.49% in the next year.